Results 161 to 170 of about 221,455 (333)

Rituximab in Severe Lupus Nephritis

, 2009
BACKGROUND AND OBJECTIVES: Standard treatment for lupus nephritis, including corticosteroids and cyclophosphamide, is efficient but is still associated with refractory or relapsing disease, or severe deleterious effects.
Catherine Melander, Elie, C., Pierre Trolliet, Karras, A., Phillipe Re[Combining Acute Accent]my, Belenfant, X., Christian Jacquot, Philippe Lesavre, Zarrouk, V., Fakhouri, F., Knebelmann, B., Lesavre, P., Jacquot, C., Jean-Jacques Boffa, Xavier Belenfant, Bertrand Knebelmann, Virginie Zarrouk, Alexandre Karras, Sophie Candon, Evange[Combining Acute Accent]line Pillebout, Sallee, M., Caroline Elie, Noel, L. H., Brocheriou, I., Candon, S., Remy, P., Virginie Masse, Eric Daugas, Masse, V., Isabelle Brocheriou, ne Laure-He[Combining Acute Accent]le[Combining Grave Accent] Noe[Combining Diaeresis]l, Fadi Fakhouri, Trolliet, P., Daugas, E., Marion Salle[Combining Acute Accent]e, Melander, C., Boffa, J. J., Pillebout, E.   +37 more
core   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases

Pharmacology Research & Perspectives
Rituximab is an anti‐CD20 monoclonal antibody used in autoimmune diseases, including glomerular diseases. The FCGR2A (rs1801274) and FCGR3A (rs396991) variants have been suggested to affect rituximab efficacy; this study evaluates their impact on ...
María Larrosa‐García, Irene Agraz Pamplona, Susana Rojo Tolosa, Alberto Jiménez Morales, María Teresa Sanz Martínez, Mónica Martínez Gallo, Roger Colobran, Helena Genestal Vicente, Nerea Moreno Pena, Roxana Paola Bury Macías, José Bruno Montoro Ronsano   +10 more
doaj   +1 more source

Transition of Thyroid Autoantibodies by Rituximab Treatment in Women with Rheumatoid Arthritis [PDF]

Rituximab was first used as a treatment for B-cell malign lymphoma, and it is currently used in the treatment of rheumatoid arthritis. On the other hand, an association between rheumatoid arthritis with another autoimmune disease Hashimoto’s thyroiditis ...
Hüseyin Demirci, Bilge Ceydilek, Ebru Aydoğan, AYDOĞAN, EBRU, Demirci, Huseyin, Ceydilek, Bilge   +5 more
core   +1 more source

Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression

Arthritis &Rheumatology, EarlyView.
Objective Sjögren disease (SjD) is a heterogeneous autoimmune disease. We aimed to investigate blood transcriptomic signatures and disease progression among three recently defined clusters of patients with SjD: (1) B cell active disease with low symptom burden (BALS), (2) high systemic activity (HSA), and (3) low systemic activity with high symptom ...
Sacha E. Silva‐Saffar, Yann Nguyen, Raphaèle Seror, Jacques‐Eric Gottenberg, Anna Niarakis, Xavier Mariette, Gaetane Nocturne   +6 more
wiley   +1 more source

Increased Plasma Microbial tDR‐1 in At‐Risk Individuals Is Associated With Decreased Conversion to Clinical Rheumatoid Arthritis and Reduces an In Vitro Macrophage Type 1 Interferon Response

Arthritis &Rheumatology, EarlyView.
Objective Microbial small RNAs can regulate human genes. Higher plasma concentrations of microbial transfer RNA (tRNA)‐derived RNA‐1 (tDR‐1) were previously associated with lower rheumatoid arthritis (RA) disease activity. This study examined whether tDR‐1 concentrations differ in anticyclic citrullinated peptide‐3 positive (CCP3+) at‐risk individuals (
Anastasiia Phothisane, Tulsi K. Joishy, Carolina Ramirez‐Becerra, Qiong Wu, Jennifer Seifert, Marie L. Feser, Jill M. Norris, M. Kristen Demoruelle, LauraKay Moss, Kevin D. Deane, V. Michael Holers, Michelle J. Ormseth   +11 more
wiley   +1 more source

Anti-CD20 (rituximab) treatment improves atopic eczema

, 2008
BACKGROUND: Atopic eczema (AE) is a chronic inflammatory skin disorder characterized by eczematous skin lesions, pruritus, and typical histopathologic features.
Simon, Hans-Uwe, Nikhil Yawalkar, Kostylina, Ganna, Hans-Uwe Simon, Hösli, Susanne, Dagmar Simon, Susanne Hösli, Simon, Dagmar, Yawalkar, Nikhil, Ganna Kostylina, Hösli S, Simon HU, Yawalkar N, Simon D, Kostylina G   +14 more
core   +1 more source

Outcomes in Progressive Pulmonary Fibrosis in Systemic Autoimmune Rheumatic Diseases: Real‐World Data From the ILD‐PRO Registry

Arthritis &Rheumatology, EarlyView.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease–associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J. Bracken, Jeremy M. Weber, Megan L. Neely, Aparna C. Swaminathan, Scott M. Palmer, Erin M. Wilfong, Ann D. Chauffe, Elizabeth R. Volkmann   +7 more
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Patients with infusion-related reactions on fixed-dose rituximab treatment have higher body surface area than those without infusion-related reactions in adults with frequently relapsing minimal change nephrotic syndrome: a retrospective study

Journal of Pharmaceutical Health Care and Sciences
Background Infusion-related reactions (IRRs) are major side effects of rituximab administration. Male sex, high body weight, body surface area (BSA), and body mass index are predictive markers of rituximab-induced IRRs.
Hironobu Nishiura, Masaya Takahashi, Katsuhito Mori, Takashi Sugimoto, Masanori Emoto, Yasutaka Nakamura   +5 more
doaj   +1 more source